A woman sitting down in a test lab looking at some test tubes

Therapeutic focus » Projects

A compound with therapeutic potential

OUR FOCUS is on PN6047, a novel potent, selective and biased signalling delta-opioid receptor agonist, which is predicted to reduce common symptoms of chronic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.

In various pre-clinical studies, PN6047 has shown high selectivity and potency, and very convincing efficacy in reducing neuropathic pain without any signs of the unwanted side effects of traditional opioids such as respiratory depression, abuse potential and the development of tolerance.

PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favourable dosing in humans.

PN6047 has fully drug-able properties and characteristics enabling the production of a commercial solid dosage form.

Latest news

View all
May 2, 2023

PharmNovo attending LSX 3–4 May

PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.

Read more
May 2, 2023

Jesper Kjerulff leads again

PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.

Read more
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.